Laser capture microdissection as a tool to evaluate human papillomavirus genotyping and methylation as biomarkers of persistence and progression of anal lesions
Alyssa M Cornall, J M Roberts, Monica Molano, Dorothy A Machalek, Samuel Phillips, Richard J Hillman, Andrew E Grulich, Fengyi Jin, I Mary Poynten, David J Templeton, …
Introduction: Anal squamous cell carcinoma is preceded by persistent infection with high-risk human papillomavirus (HPV) and the cancer precursor, high-grade squamous intraepithelial lesion (HSIL). Detection of specific HPV genotypes and HPV-related biomarkers may be an option for primary anal screening. However, more data on the natural history of HPV-related anal lesions are required. The outcomes from this study will enhance our understanding of the clinical and biological behaviour of HPV-related anal lesions and inform the development of future HPV genotype and/or biomarker screening tests.
Methods and analysis: HIV-negative and HIV-positive men who have sex with men, aged 35 years and over, recruited from community-based settings in Sydney, Australia, attend 6 clinic visits over 3 years. At the first 5 visits, participants undergo a digital anorectal examination, an anal swab for HPV genotyping and anal cytology, and high-resolution anoscopy with directed biopsy of any visible abnormalities that are suggestive of any abnormality suspicious of SIL. Tissue sections from participants diagnosed with histologically confirmed HSIL at the baseline clinic visit will undergo laser capture microdissection, HPV detection and genotyping, and quantitation of CpG methylation in baseline and follow-up biopsies. Histological and cytological findings in combination with HPV genotyping data will be used to identify persistent HSIL. HSIL will be stratified as non-persistent and persistent based on their status at 12 months. The performance of HPV genotype and methylation status in predicting disease persistence at 12 months will be assessed, along with associations with HIV status and other covariates such as age.
Ethics and dissemination: The St Vincent's Hospital Ethics Committee granted ethics approval for the study. Written informed consent is obtained from all individuals before any study-specific procedures are performed. Findings from this study will be disseminated to participants and the community through study newsletters, and through peer-reviewed publications and international conferences.
Details
Title
Laser capture microdissection as a tool to evaluate human papillomavirus genotyping and methylation as biomarkers of persistence and progression of anal lesions
Authors
Alyssa M Cornall - Royal Women's Hospital
J M Roberts - Douglass Hanly Moir Pathology
Monica Molano - Royal Women's Hospital
Dorothy A Machalek - Royal Women's Hospital
Samuel Phillips - Royal Women's Hospital
Richard J Hillman - The University of Sydney
Andrew E Grulich - UNSW Sydney
Fengyi Jin - UNSW Sydney
I Mary Poynten - UNSW Sydney
David J Templeton - UNSW Sydney
Suzanne M Garland - Royal Women's Hospital
Sepehr N Tabrizi - Royal Women's Hospital
SPANC Study Team (Research Group)
Publication details
BMJ Open, Vol.5(8), pp.1-12
Publisher
BMJ Group
Date published
2015
DOI
10.1136/bmjopen-2015-008439
ISSN
2044-6055
PMID
26310402
Copyright note
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Grant note
The SPANC study is funded by Australian Commonwealth Government National Health and Medical Research Council Program grants (#568971 and #1071269) and a Cancer Council New South Wales Strategic Research Partnership Program grant (#13-11).
Organisation Unit
School of Health - Biomedicine; Centre for Bioinnovation